There are well-recognised harms from long-term use of benzodiazepines. These include dependency, cognitive decline and falls.

It is important to prevent and recognise benzodiazepine dependence. A thorough risk assessment guides optimal management and the necessity for referral.

The management of dependence involves either gradual benzodiazepine withdrawal or maintenance treatment. Prescribing interventions, substitution, psychotherapies and pharmacotherapies can all contribute.

Unless the patient is elderly, it is helpful to switch to a long-acting benzodiazepine in both withdrawal and maintenance therapy. The dose should be gradually reduced over weeks to lower the risk of seizures.

Harms from drugs such as zopiclone and zolpidem are less well characterised. Dependence is managed in the same manner as benzodiazepine dependence.



Despite a modest decrease in the annual number of benzodiazepine prescriptions dispensed, the current level of prescribing probably represents significant overuse. Over the last 20 years the quantity of benzodiazepines on each prescription has increased. Alprazolam became the second most popular drug, increasing more than eightfold.1 Of particular concern are the patients who have been using benzodiazepines for more than six months. There are few indications for long-term therapy and they are generally controversial.2

Benzodiazepine-related problems include diversion, misuse, dependency, driving impairment, and morbidity and mortality related to overdose and withdrawal. In older patients they have been associated with cognitive decline, dementia3 and falls.4,5 There is evidence of increased mortality with long-term use.6

In February 2014, in response to increasing illicit use, alprazolam was rescheduled to Schedule 8. It has greater toxicity in overdose,7 and associated mortality8 relative to other benzodiazepines. The public health impact of this rescheduling is yet to be determined. This barrier to prescribing has placed renewed focus on benzodiazepine dependence. However, there is a paucity of research on the optimal management of benzodiazepine dependence, so practice has to be guided by general principles.



Any patient who has taken a benzodiazepine for longer than 3–4 weeks is likely to have withdrawal symptoms if the drug is ceased abruptly. The risk of inducing dependence can be reduced by issuing prescriptions limited to 1–2 weeks supply.

Benzodiazepines are often prescribed for insomnia and anxiety. In general, the optimal treatment of these conditions in primary care is non-pharmacological, particularly psychological and behavioural, therapies. Because of tolerance and withdrawal symptoms, long-term use of benzodiazepines can lead to dose escalation and worsening of the underlying condition.


Recognition and assessment

The benzodiazepine-dependent population is heterogeneous and this influences management. A frail 70 year old with falls prescribed flunitrazepam as a sedative hypnotic for 20 years requires a different management approach from a 25-year-old intravenous drug user buying street alprazolam. The principles of management of dependence with ‘z-drugs’ such as zolpidem and zopiclone are the same as the management of benzodiazepine dependence.

Benzodiazepine substance use disorder can be diagnosed using DSM-5 criteria,9 but the Severity Dependence Scale is a simple screening tool validated for use in the community.10 Some patients prescribed benzodiazepines may have aberrant drug-related behaviours, ranging from double dosing to selling medicines illicitly or injecting them. Systems limitations in prescription monitoring in Australia reduce our ability to identify ‘doctor shopping’ so the presence of any aberrant drug-related behaviours should prompt further assessment and treatment.

The assessment determines the severity of misuse and informs the risk of relapse and of harm. It should include the indication for prescribing, dose, duration of use, age and any history of psychiatric or medical comorbidity as well as any other past or current substance misuse. Assess for benzodiazepine substance use disorder and the severity of aberrant drug-related behaviours. Supportive social networks and stable housing are positive prognostic indicators. Assessing the patient’s readiness to change guides the initial management.



Patient engagement in management is essential as without this any attempts to address harmful use may be hindered by non-adherence or even doctor shopping. If the patient is not ready to change, or is just considering change, then motivational interviewing techniques are recommended. If the patient is ready for change, there are two approaches to the management of dependence:

  • benzodiazepine withdrawal with the aim of abstinence
  • benzodiazepine maintenance therapy.

The choice of approach depends on an assessment of the risk of harm and relapse. Low-risk patients can be managed in general practice and may benefit most from attempting withdrawal. High-risk patients are best managed with initial stabilisation and maintenance therapy in specialist residential or outpatient addiction services. There are general principles that apply to both groups.

Prescribing interventions

Staged dispensing is effective in both withdrawal and maintenance. This can be done by regular dispensing of small quantities at a local pharmacy with clinical review, for example daily dispensing with fortnightly clinical review. Liaison with a community pharmacist is a useful strategy.

Benzodiazepine substitution

Some benzodiazepines, notably alprazolam, appear to have a greater propensity for misuse and are more dangerous in overdose. The reasons for this are multifactorial, including perception of intoxication, potency relative to formulation (e.g. a single 2 mg alprazolam tablet is equivalent to four 5 mg diazepam tablets), shorter half-life and risk of withdrawal phenomena. A common approach is substituting these shorter half-life drugs, such as alprazolam, with longer half-life drugs, such as diazepam.11 Conversion tables are available to guide conversion to diazepam equivalents (Table). When tapering benzodiazepines, fewer patients taking longer half-life drugs drop out, however there is a lack of robust evidence supporting substitution. Studies in older patients have found gradual withdrawal without substitution can be successful.12,13

Table: Benzodiazepine and z-drugs half-life and conversion table
Drug Approximate half-life (hours) Dose of oral benzodiazepine approximately equivalent to diazepam 5 mg
Short- to intermediate-acting benzodiazepines
Triazolam 1–3 0.25 mg
Oxazepam 4–15 15 mg
Temazepam 5–15 10 mg
Lorazepam 12–16 1 mg
Bromazepam 20 3 mg
Alprazolam 6–25 0.5 mg
Flunitrazepam 20–30 0.5 mg
Nitrazepam 16–48 5 mg
Clobazam 17–49 10 mg
Long-acting benzodiazepines (includes effects of active metabolites)
Clonazepam 22–54 0.5 mg
Diazepam 20–80 5 mg
Zolpidem 2.4 10 mg
Zopiclone 5.2 7.5 mg


When treatment is offered, ensure the patient is not doctor shopping to obtain more prescriptions. Doctors can register with Medicare’s Prescription Shopping Information Service which provides a limited telephone report. However, this relies on doctors calling the program rather than being alerted automatically. With written patient consent, authority can be gained to release information on Pharmaceutical Benefits Scheme prescriptions over a given time period.14

Urine drug screening is complicated by the presence of benzodiazepine metabolites. Care should be taken in interpreting the results as some metabolites are themselves parent compounds. For example, temazepam and oxazepam are metabolites of diazepam, which may lead the practitioner to conclude that the patient had been taking other benzodiazepines during diazepam treatment. Urine drug screening should be used as a tool to engage the patient rather than as a punitive measure.

Discontinuation with the aim of abstinence

Long-term abstinence rates following discontinuation vary greatly. These range from 25% at 12 months for those with complicated dependence15 to 80% for older adults in general practice.16 Abrupt cessation of benzodiazepines after a period of 1–6 months of use can cause life-threatening seizures so the dose should be gradually reduced.

The duration of weaning depends on tolerability and the starting dose. While not specifying a withdrawal period, most studies in primary care have found that gradual withdrawal over at least 10 weeks is successful in achieving long-term abstinence.12

Patients with a lower risk of relapse are those taking a daily dose of 10 mg diazepam equivalent or less at the start of tapering, and those who have made a substantial dose reduction themselves before the start of tapering. Other low-risk characteristics are less severe benzodiazepine dependence (measured on a dependence scale), no previous withdrawal attempts, high life satisfaction and no use of alcohol.15,17 Patients without unstable psychiatric or medical comorbidity, no history of seizures and no concurrent drug abuse or dependence are also at a lower risk of harm from benzodiazepine withdrawal.

Patients may find that the symptoms of withdrawal (see Box) are typical of their previous problems such as insomnia or anxiety. This should be discussed with them, and psychotherapy or appropriate pharmacotherapy offered.

There are no standard tapering regimens and the rate of tapering depends on the starting dose, duration of therapy, risk of relapse and how well tapering is tolerated by the patient. In general, at higher doses (e.g. greater than 10 mg diazepam equivalents per day) the dose may be tapered more rapidly. Once the patient achieves 10 mg the dose should be tapered more slowly (e.g. 5 mg twice daily for two weeks, then once daily for two weeks, and then 2 mg daily for two weeks and then cease).

Box: Benzodiazepine withdrawal syndrome – clinical features






Tremor, fasciculations

Muscle pain, stiffness and aches (limbs, back, neck, jaw)


Dizziness, light-headedness

Paraesthesia, shooting pains in neck and spine

Visual disturbances (blurred vision, diplopia, photophobia, vision lags behind eye movements)


Faintness and dizziness, sense of unsteadiness

Confusion, disorientation (may be intermittent) – a common cause of confusion in older patients

Delirium (in the absence of autonomic hyperactivity) – particularly in older patients

Delusions, paranoia

Hallucinations (visual, auditory)

Grand mal seizures 1–12 days after discontinuing benzodiazepines




Diarrhoea (may resemble irritable bowel syndrome)


Rebound insomnia, nightmares

Anxiety, panic attacks

Irritability, restlessness, agitation

Poor memory and concentration

Perceptual distortions – sensory hypersensitivity (light, sound, touch, taste), abnormal sensations (e.g. ‘cotton wool’ sensations)

Metallic taste

Distortions of body image

Feelings of unreality, depersonalisation, derealisation

Depression, dysphoria


Anticonvulsants have some efficacy in benzodiazepine withdrawal if the patient is not dependent on other drugs. Carbamazepine has a modest benefit12 and pregabalin can be effective.18 Antidepressants and beta blockers have no proven benefit.

Flumazenil, a GABAA receptor antagonist, has been used as a low-dose intravenous or subcutaneous infusion over four days to help patients rapidly withdraw from benzodiazepines to a lower dose or to abstinence without significant withdrawal symptoms. A proposed mechanism is reversal of receptor desensitisation and down regulation. There are some data showing effectiveness, albeit in small groups of patients.19 Although relatively uncommon, seizures can occur with low-dose flumazenil infusion and so it should only be considered in a specialised unit.2


A meta-analysis of treatment for benzodiazepine discontinuation found that gradual dose reduction combined with psychological treatment was superior to gradual dose reduction alone.21 A recent Cochrane review assessed randomised controlled trials of many different psychosocial interventions. It found only moderate evidence that adding cognitive behavioural therapy during taper was more effective than just tapering the dose. There was insufficient evidence to make any conclusions regarding motivational interviewing. Interventions that could reduce benzodiazepine use include a tailored letter from the patient’s GP advising reducing or quitting the drug, standardised interviews and relaxation techniques.22

Stabilisation and maintenance therapy

Some patients are reluctant to consider ceasing their benzodiazepine and are at high risk of relapse or harm. A harm reduction strategy may be more appropriate for this group. This involves using a long half-life substitute to prevent intoxication and withdrawal phenomena, and allowing the patient to engage in holistic treatment of their dependence, before slowly reducing the dose.

Patients who may need maintenance therapy are those who are on a high diazepam equivalent dose, have a range of aberrant drug-related behaviours (especially doctor shopping) and have a chaotic social setting or unstable psychiatric diagnoses. Patients who are alcohol or drug dependent may also benefit from this approach.23 These people are often difficult to manage and should be referred to a specialist addiction service. To support management in rural and remote settings, health professionals in all states and territories have access to 24-hour phone support services.24

Patients on maintenance therapy may eventually reach a period of stability in which withdrawal to a lower dose or abstinence may be considered. High-risk patients or those with unstable medical conditions or a significant seizure history may benefit from admission to an inpatient service for stabilisation or withdrawal.



There is significant concern regarding overprescribing of benzodiazepines and the resultant harms. People who are benzodiazepine dependent or at risk because of misuse should be identified and appropriately assessed to determine their risk of harm. Depending on patient characteristics, benzodiazepines can be withdrawn or the patient stabilised on a maintenance program.

Prescribing interventions, substitution, psychotherapies and pharmacotherapies all contribute to the management of benzodiazepine dependence. However, some of these interventions have limited supporting evidence. There is therefore a need to develop a better evidence base and treatment paradigm for these patients.

Conflict of interest: none declared



  1. Islam MM, Conigrave KM, Day CA, Nguyen Y, Haber PS. Twenty-year trends in benzodiazepine dispensing in the Australian population. Intern Med J 2014;44:57-64.
  2. Lader M. Benzodiazepines revisited--will we ever learn? Addiction 2011;106:2086-109.
  3. Billioti de Gage S, B\u00e9gaud B, Bazin F, Verdoux H, Dartigues JF, P\u00e9r\u00e8s K. Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012;345:e6231.
  4. Pariente A, Dartigues JF, Benichou J, Letenneur L, Moore N, Fourrier-R\u00e9glat A. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging 2008;25:61-70.
  5. Ballokova A, Peel NM, Fialova D, Scott IA, Gray LC, Hubbard RE. Use of benzodiazepines and association with falls in older people admitted to hospital: a prospective cohort study. Drugs Aging 2014;31:299-310.
  6. Charlson F, Degenhardt L, McLaren J, Hall W, Lynskey M. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiol Drug Saf 2009;18:93-103.
  7. Isbister GK, O\u2019Regan L, Sibbritt D, Whyte IM. Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol 2004;58:88-95.
  8. Rintoul AC, Dobbin MD, Nielsen S, Degenhardt L, Drummer OH. Recent increase in detection of alprazolam in Victorian heroin-related deaths. Med J Aust 2013;198:206-9.
  9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013. .
  10. de las Cuevas C, Sanz EJ, de la Fuente JA, Padilla J, Berenguer JC. The Severity of Dependence Scale (SDS) as screening test for benzodiazepine dependence: SDS validation study. Addiction 2000;95:245-50.
  11. Liebrenz M, Boesch L, Stohler R, Caflisch C. Agonist substitution--a treatment alternative for high-dose benzodiazepine-dependent patients? Addiction 2010;105:1870-4.
  12. Denis C, Fats\u00e9as M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 2006;3:CD005194.
  13. Campbell AJ, Robertson MC, Gardner MM, Norton RN, Buchner DM. Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. J Am Geriatr Soc 1999;47:850-37.
  14. Australian Government Department of Human Services. Prescription Shopping Information Service. Canberra: DHS; 2015. [cited 2015 Sep 7]
  15. Vorma H, Naukkarinen H, Sarna S, Kuoppasalmi K. Long-term outcome after benzodiazepine withdrawal treatment in subjects with complicated dependence. Drug Alcohol Depend 2003;70:309-14.
  16. Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med 2003;33:1223-37.
  17. Voshaar RC, Gorgels WJ, Mol AJ, van Balkom AJ, Mulder J, van de Lisdonk EH. Predictors of long-term benzodiazepine abstinence in participants of a randomized controlled benzodiazepine withdrawal program. Can J Psychiatry 2006;51:445-52.
  18. Oulis P, Konstantakopoulos G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opin Investig Drugs 2012;21:1019-29.
  19. Hood SD, Norman A, Hince DA, Melichar JK, Hulse GK. Benzodiazepine dependence and its treatment with low dose flumazenil. Br J Clin Pharmacol 2014;77:285-94.
  20. Lugoboni F, Faccini M, Quaglio GL, Albiero A, Casari R, Pajusco B. Intravenous flumazenil infusion to treat benzodiazepine dependence should be performed in the inpatient clinical setting for high risk of seizure. J Psychopharmacol 2011;25:848-9.
  21. Parr JM, Kavanagh DJ, Cahill L, Mitchell G, McD Young R. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction 2009;104:13-24.
  22. Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Libr 2015;.
  23. Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A. Treatment of benzodiazepine dependence in methadone maintenance treatment patients: a comparison of two therapeutic modalities and the role of psychiatric comorbidity. Aust N Z J Psychiatry 2003;37:458-63.
  24. National Drugs Campaign. Need Help? Help in your state. Canberra: Department of Health; 2014 Mar. [cited 2015 Sep 7]

Jonathan Brett

Staff specialist, Clinical Pharmacology and Addiction Medicine, Drug Health Services, Royal Prince Alfred Hospital

Bridin Murnion

Senior staff specialist, Clinical Pharmacology and Addiction Medicine, Drug Health Services, Royal Prince Alfred Hospital

Senior staff specialist, Concord Repatriation General Hospital, Sydney